Organon China attends the CIIE again, focusing on women’s health and firmly investing in China

Organon China attends the CIIE again, focusing on women’s health and firmly investing in China

November 5, 2023, Shanghai, China - Organon China made its debut at the 6th China International Import Expo (hereinafter referred to as the "CIIE") with the theme of "Her Health, Sharing the Future". As one of the few women's health companies in the industry with Fortune 500 scale, extensive network coverage, and first-class business operation capabilities, Organon China will display its localized development blueprint of "building China, benefiting China, and benefiting the world" at its 800-square-meter booth, its "whole reproductive cycle" and "whole life cycle" health care layout that it is committed to building for women and their families, and its solid commitment to benefiting the majority of women in China and the thousands of families behind them.

Zafer Unluer, Organon China's global senior vice president and president of China, said: "The CIIE is not only a 'result show' for Organon China's development in China for more than two years, but also a 'golden key' to open new opportunities for cooperation. This year is Organon China is participating in the CIIE for the second time. We have really benefited from the extensive spillover effect of the CIIE. Some new products have achieved rapid transformation from "exhibits" to the market. We have also found opportunities for local business cooperation and implemented them through this platform. Organon China is a company born for women's health. As we implement the localization development strategy and improve the health accessibility of Chinese patients, our development path in China will become wider and wider. China looks forward to deepening mutual trust with the government and cross-sector partners, jointly promoting innovation, improving access, and supporting the construction of a healthy China and the high-quality development of China’s maternal and child health industry; at the same time, we also hope to grow together with local partners and help China’s local innovative solutions go out of China and benefit the world.”

Major exhibits unveiled to serve the health needs of hundreds of millions of Chinese women and families

From "first-time visitors" to "repeat visitors" at the CIIE, Organon China continues to innovate, bringing a series of diversified innovative products and solutions involving the "whole reproductive cycle" and "whole life cycle" of women and their families, including the "CIIE Baby" that has moved from "exhibits" to the market, and a number of highlight exhibits that are "China's only" and have not yet been approved in China:

• In September this year, the innovative compound preparation in the cardiovascular field, Irito® [generic name: Ezetimibe and Atorvastatin Calcium Tablets (Ⅰ)/(Ⅱ)], was approved in China and made its debut again. As Organon China’s first “CIIE baby”, it moved from the CIIE booth to the market in just 10 months, bringing convenient new lipid-lowering treatment strategies to Chinese patients;
• Xinma Fulong® [generic name: desogestrel ethinylestradiol tablets], which was re-launched in China in July this year, made its debut at the CIIE. This is the first and so far the only compound oral contraceptive with indications for menstrual cycle regulation in China;
• So far, China’s only approved single-root subcutaneously implanted contraceptive product, Epanon® [generic name: etonogestrel implant], is a “fertility-friendly” long-acting contraceptive solution that protects female fertility;
• The innovative medical device 1 used to treat postpartum hemorrhage helps deal with birth complications that seriously threaten maternal life and promotes perinatal health. Organon China plans to accelerate the introduction of this product into China.

Taking advantage of the opportunity of the CIIE, Organon China will comprehensively display innovative layouts involving women's "whole reproductive cycle", from contraception to childbearing, protecting female fertility, helping women of childbearing age to both "have a good birth" and "have a good birth", and help thousands of Chinese families achieve their fertility goals. At the same time, Organon China will also present its "full life cycle" solutions for women from adolescence, childbearing age to menopause, as well as classic brands that are familiar to many medical professionals and patients in core disease fields such as respiratory, cardiovascular, skin, pain, bone health, men's health, and central nervous system. From children, teenagers, middle-aged to the elderly, Organon China is committed to protecting the health of Chinese women and the families behind them throughout their lives. In the future, Organon China plans to launch at least one new product in China every year, so that global innovation results can benefit China more quickly.

Resolutely invest in China and resonate with "Healthy China"

At this CIIE, Organon China will showcase the world's increasingly rich innovative R&D pipeline layout to help deal with common female-specific diseases including endometriosis and polycystic ovary syndrome that have long lacked targeted solutions. Organon China will also review the strategic cooperation it has established with local Chinese companies in assisted reproduction, protection of female fertility, and response to male androgenetic alopecia, etc., to promote the progress of local innovative pharmaceutical research and development in China, further help Chinese wisdom and experience to radiate around the world, and allow patients around the world to share innovative health results from China.

During the CIIE, Organon China will hold a series of booth activities to comprehensively demonstrate the company's innovative practices of co-creation and win-win in the four aspects of academics, diagnosis and treatment, retail and digitalization in conjunction with the industry ecosystem. Through exploration and promotion of wide access to high-quality medical services, Organon China will make long-term and far-reaching contributions to improving the health of women and their families in China and around the world.

Previous CIIEs have been an important stage to witness the high-quality development of China's opening-up and the upgrading of its medical and health services. Organon China has clearly seen the huge unmet health needs of the Chinese market, its ever-changing industrial progress, and its huge potential to leverage global pharmaceutical innovation. China is Organon China's second largest market in the world. Organon China benefits from the Chinese government's open policy and continuously optimized business environment. It will firmly implement the local development strategy of "building China, benefiting China, and benefiting the world", continuously integrate into China's new development pattern, deeply participate in and support the prosperity and development of China's maternal and child health industry, and strive to become a trustworthy partner in building a "Healthy China Strategy" and a "reproductive-friendly society".

About Organon China

Organon China (NYSE: OGN) is a global medical and health company spun out from Merck & Co., focusing on protecting women's health throughout their life cycle and bringing women and their families a healthier and better life every day. Because of her, Organon China provides a product portfolio of more than 60 drugs and medical solutions around the world, covering a range of disease treatment areas. Relying on the reproductive health business, the continuously growing biosimilar business, and the stable classic brand business, Organon China can continue to invest in future growth and business expansion opportunities in the field of women's health with strong cash flow advantages. In addition, Organon China is also actively exploring cooperation with innovative biopharmaceutical companies to leverage the company's scale and resource advantages in the rapidly growing international market to help them commercialize their products.

Organon China has achieved large-scale and wide-coverage development around the world and has world-class commercial operation capabilities. It is headquartered in Jersey City, New Jersey, USA, and has more than 10,000 employees worldwide.

About Organon ChinaChina

Organon China is a leading global medical and health company focused on protecting women's health throughout their life cycle.

China is a vital part of Organon China's global strategic blueprint. Organon China China is headquartered in Shanghai. Adhering to our unchanging commitment to patients, we actively respond to China's maternal and child development policy and are committed to comprehensively protecting the health of Chinese women and families through more than 20 types of drugs and medical solutions covering seven major disease treatment areas: fertility, contraception, respiratory, cardiovascular, skin, pain, and bone health.

"Creating a healthier and better day for every woman" is Organon China's unchanging vision. In China, we are deeply engaged in the two core businesses of women's health and classic brands, and are committed to becoming a practical pioneer in China's pharmaceutical retail innovation model. We are passionate and wholeheartedly work with partners from all walks of life to explore diversified solutions to meet the huge unmet health needs of Chinese women and help Chinese women and the hundreds of millions of families behind them achieve a healthier and better life every day.

For more information, please visit Organon China's official website Organonchina.com.cn or follow our official WeChat public account "Organon China" (OrganonChina).